Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Aktis Oncology (NASDAQ:AKTS) have been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $35.62.

AKTS has been the topic of a number of recent analyst reports. Raymond James Financial started coverage on shares of Aktis Oncology in a report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price target on the stock. HC Wainwright upped their price objective on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Oppenheimer started coverage on shares of Aktis Oncology in a report on Wednesday, September 9th. They set an “outperform” rating and a $40.00 price target on the stock. Wedbush began coverage on shares of Aktis Oncology in a research note on Wednesday, August 19th. They set an “outperform” rating and a $35.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Aktis Oncology in a research note on Friday, September 18th.

Insider Transactions at Aktis Oncology

In related news, Director Ken Herrmann sold 4,856 shares of the business’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $24.56, for a total value of $119,263.36. Following the sale, the director directly owned 3,506 shares in the company, valued at approximately $86,107.36. The trade was a 58.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 3.30% of the company’s stock.

Hedge Funds Weigh In On Aktis Oncology

Large investors have recently made changes to their positions in the company. Tidal Investments LLC purchased a new stake in shares of Aktis Oncology during the second quarter valued at about $1,839,000. Squarepoint Ops LLC purchased a new stake in Aktis Oncology in the 2nd quarter worth approximately $1,237,000. Readystate Asset Management LP purchased a new position in shares of Aktis Oncology in the 2nd quarter valued at about $967,000. AXQ Capital LP purchased a new position in Aktis Oncology during the second quarter valued at $226,000. Finally, Susquehanna International Group LLP purchased a new position in Aktis Oncology in the 2nd quarter valued at $278,000. 28.84% of the stock is owned by hedge funds and other institutional investors.

Aktis Oncology Price Performance

Shares of AKTS stock opened at $19.63 on Friday. The company’s fifty day simple moving average is $24.07 and its two-hundred day simple moving average is $22.15. The stock has a market capitalization of $1.06 billion and a price-to-earnings ratio of -23.94. Aktis Oncology has a 1 year low of $14.72 and a 1 year high of $34.19.

Aktis Oncology (NASDAQ:AKTS) last released its quarterly earnings results on Thursday, August 13th. The technology company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). The firm had revenue of $3.38 million for the quarter, compared to analysts’ expectations of $2.70 million. Equities research analysts anticipate that Aktis Oncology will post -1.82 EPS for the current year.

About Aktis Oncology

Aktis Oncology, Inc is a clinical-stage biotechnology company focused on developing precision cancer treatments. The company’s research is centered on targeted alpha therapies, which are designed to deliver highly potent radiation directly to cancer cells while limiting exposure to surrounding healthy tissue.

Aktis Oncology is developing a pipeline of investigational therapies for solid tumors and other cancers. Its programs are intended to use tumor-targeting molecules to selectively transport radioactive payloads to cancer cells, with the goal of improving treatment effectiveness and addressing cancers that may be difficult to treat with conventional approaches.

The company’s product candidates remain in development and are subject to clinical, regulatory and commercial risks.